Please login to the form below

Not currently logged in
Email:
Password:

Corlanor

This page shows the latest Corlanor news and features for those working in and with pharma, biotech and healthcare.

Trial of Amgen, Servier’s heart failure drug clears interim check

Trial of Amgen, Servier’s heart failure drug clears interim check

The approvals of Novartis’ Entresto (sacubitril/valsartan) and Amgen/Servier's Corlanor (ivabradine) in 2015 provided some new treatment options however, and there are signs that the flow of new drugs

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Origins - The Patient Focused Specialists

Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...

Latest intelligence

ASH 2022: bad blood but big advances
Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...